BeOne Medicines AGEigentümerstruktur
| Preis (2026-07-30) | 52W Hoch | 52W Tief |
| 196.1 HKD | 229,4 HKD | 153 HKD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| - HKD | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 1.233.710.562 | - | - |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name BeOne Medicines AG
Mitarbeiter 12.000
Handelsplatz HK
Ticker Symbol 6160
IPO Datum -
Adresse 94 Aeschengraben 27, Basel, Switzerland, 4051
Webseite https://beonemedicines.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO |
| 2 | Mr. Wang Lai Ph.D. | President and Global Head of Research & Development |
| 3 | Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder |
| 4 | Mr. Aaron Rosenberg | Chief Financial Officer |
| 5 | Mr. Chan Lee | General Counsel, Senior VP & Corporate Secretary |
| 6 | Mr. Titus B. Ball | VP & Chief Accounting Officer |
| 7 | Mr. Marcello Damiani | Chief Technology Officer |
| 8 | Ms. Liza Heapes | Head of Investor Relations |
| 9 | Ms. Eleanor Duff Ph.D. | Senior VP & Head of Corporate Communications |
| 10 | Mr. Graham Hardiman | Global Head of Human Resources |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
Für dieses Unternehmen liegen derzeit keine Daten zu institutionellen Investoren vor.